联合分子检测与Bethesda III:VI比值:甲状腺细针穿刺的质量保证指标
该研究在7382例甲状腺FNA活检中评估AUS率和III:VI比值,并对588例进行分子检测。结果显示AUS率为9.3%,III:VI比值整体2.4,NGA率与诊断比值不相关,提示联合NGA率和III:VI比值可校准诊断阈值。
要点
- AUS率整体9.3%,6位细胞病理医生间范围4.3%-24.2%。
- III:VI比值整体2.4(范围1.1-8.1),(III+IV):VI比值整体2.9(范围1.4-9.5)。
- AUS病例NGA率与III:VI或(III+IV):VI比值不相关。
核心结论
- NGA率与易计算的诊断比值不相关,使得即使对指标正常的细胞病理医生也能校准诊断阈值。
- 计算NGA率和III:VI比值可能帮助个体细胞病理医生判断是否过度或不足诊断。
研究设计与样本
- 回顾性分析7382例甲状腺FNA活检,评估AUS率和III:VI比值。
- 对588例来自560例患者(79%女性,中位年龄56岁,范围8-89岁)的病例进行分子检测。
主要发现
- AUS率整体9.3%,在评估>150例的6位细胞病理医生中范围为4.3%-24.2%。
- III:VI比值整体2.4(范围1.1-8.1),(III+IV):VI比值整体2.9(范围1.4-9.5)。
- BRAF V600E突变在TBS VI类中最常见(76%),在III类中罕见(3%)。
- RAS样突变在TBS III类(13%)、IV类(25%)和V类(17.5%)中最常见。
- AUS病例的NGA率在6位细胞病理医生中5位介于5%-20%,与III:VI比值或(III+IV):VI比值不相关。
关键数值与推荐
- AUS率整体9.3%,范围4.3%-24.2%(6位细胞病理医生,评估>150例)。
- III:VI比值整体2.4(范围1.1-8.1)。
- (III+IV):VI比值整体2.9(范围1.4-9.5)。
- BRAF V600E在VI类中占76%,在III类中占3%;RAS样突变在III类13%、IV类25%、V类17.5%。
- AUS病例NGA率在6位细胞病理医生中5位介于5%-20%。
临床怎么用
- 联合计算NGA率和III:VI比值可帮助个体细胞病理医生自我评估诊断阈值。
- 利用这些指标判断是否存在过度诊断或诊断不足,以优化AUS的使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Molecular testing (MT) of thyroid fine-needle aspiration (FNA)-derived genetic material is commonly used to assess malignancy risk for indeterminate cases. The Bethesda System for Reporting Thyroid Cytopathology (TBS) provides limited guidance for the appropriate use of category III (atypia of undetermined significance [AUS]). The authors combined MT with cytomorphology to monitor AUS diagnoses in a cytopathology laboratory. METHODS: Neoplasia-associated genetic alterations (NGAs) were determined by MT of preoperative FNA biopsies or resected malignancies and were categorized as BRAF V600E mutations, RAS-like mutations (HRAS, NRAS, or KRAS mutations or non-V600E BRAF mutations), or other mutations. RESULTS: Among 7382 thyroid FNA biopsies, the AUS rate was 9.3% overall and ranged from 4.3% to 24.2% among 6 cytopathologists (CPs) who evaluated >150 cases. The ratio of specimens falling into TBS category III to specimens falling into category VI (malignant) (the III:VI ratio) was 2.4 overall (range, 1.1-8.1), and the ratio of specimens falling into TBS categories III and IV (follicular neoplasm or suspicious for follicular neoplasm) combined (III+IV) to specimens falling into category VI (the [III+IV]:VI ratio) was 2.9 overall (range, 1.4-9.5). MT was performed on 588 cases from 560 patients (79% women) with a median age of 56 years (range, 8-89 years). BRAF V600E mutation was the most common (76% of cases) in TBS category VI and was rare (3%) in category III. RAS-like mutations were most common in TBS categories III (13%), IV (25%), and V (suspicious for malignancy) (17.5%). The NGA rate in AUS cases fell between 5% and 20% for 5 of 6 CPs and did not correlate with the III:VI ratio or the (III+IV):VI ratio. CONCLUSIONS: Lack of correlation between the NGA rate and easily calculable diagnostic ratios enables the calibration of diagnostic thresholds, even for CPs who have normal metrics. Specifically, calculation of the NGA rate and the III:VI ratio may allow individual CPs to determine whether they are overcalling or undercalling cases that other CPs might otherwise recategorize.
引用
- Gokozan HN, Dilcher TL, Alperstein SA, et al. Combining molecular testing and the Bethesda category III:VI ratio for thyroid fine-needle aspirates: A quality-assurance metric for evaluating diagnostic performance in a cytopathology laboratory. Cancer Cytopathol. 2021. PMID: 34962713. doi:10.1002/cncy.22542
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。